// Antibodies

ImmunoSigns has the Intellectual Property Right (IPR) to the monoclonal autoantibody IC2 – certainly the most pancreatic beta-cell surface specific reagent in the world.

Its use for noninvasive imaging of the pancreatic insulin-producing beta-cell mass has been highligted. This is expected be of potential clinical diagnostic importance.

Welcome to ImmunoSigns

ImmunoSigns is a Biotech company founded in 1996. We offer you help in project management and R&D activities within biotechnology and immunodetection.

The core competance of ImmunoSigns is development and production of polyclonal and monoclonal antibodies and design and production of novel immunoassays and diagnostic kits, especially within the clinical area of diabetes and obesity.

Shopping Cart